- Apr 2, 2009
- 5,171
- 13,288
- 67
Today FDA issued a Brief Summary of Not Substantially Equivalent Determinations at
http://www.fda.gov/downloads/TobaccoProducts/Labeling/MarketingandAdvertising/UCM366584.pdf
that delineates why NO e-cigarette product currently on the market could be approved as Substantially Equivalent to a product that was on the market prior to Februay 15, 2007 (unless FDA exempts e-cigs from the 2007 grandfather date in Section 910).
The FDA also announced today that it had rejected two more SE applications for tobacco products (for a total of 10 NSE decisions by FDA). Meanwhile, the FDA has only approved 9 SE applications so far (2 for cigarettes, and 7 for RYO papers and tobacco)..
Tobacco Product Marketing Orders
Yesterday, the US GAO issued a scathing report saying the FDA needs to set time frames for its review process of Substantial Equivalence (SE) applications for tobacco products since agency has made final decisions on just 17 of 3,788 SE applications filed since 2010, Senator Burr comments
http://www.gao.gov/assets/660/657451.pdf
Richard Burr, United States Senator of North Carolina: Press Releases
New Report Highlights Shortcomings in FDA Review Process - Legislative & Regulatory News - Convenience Store News
Since it's not that long, I posted the full text of the FDA's Brief Summary of "Not Substantially Equivalent" Determinations below.
Do any vapers or vendors believe that FDA would approve an SE application for any of their e-cig products? Didn't think so.
10/25/2013
Brief Summary of Not Substantially Equivalent Determinations
FDA may find a new tobacco product to be NSE either because there is inadequate
information submitted, or because FDA finds that the new product has different
characteristics and information demonstrates that it raises different questions of public
health.
Tobacco products have been found to be not substantially equivalent to specific
predicate products due to factors such as inadequate evidence that the proposed
predicate products were valid predicates and lack of complete information on the
characteristics of the new products and the predicate products. After considering all the
evidence, the agency determined that there were differences in characteristics between
the new products and the predicate products, and there was not an adequate showing
that the new products do not raise different questions of public health requiring a
premarket tobacco product application.
The types of deficiencies FDA found in one or more of these are summarized below.
Predicate
Insufficient information for FDA to determine whether or not the tobacco product
that was referenced as a predicate was predicate-eligible. Specifically, adequate
evidence was not provided to demonstrate that the predicate product was
commercially marketed in the United States as of February 15, 2007.
Design Features
Inadequate information on design features such as ventilation and filter
efficiency. This information is needed to understand if any changes in these
characteristics are present and, if they are, whether the new product raises
different questions of public health.
Tobacco Type
Inadequate information on the type of tobacco used in the cigarette. This is a
significant deficiency because the type of tobacco can alter the levels of harmful
and potentially harmful constituents. This information is needed to understand if
any changes in these characteristics are present and, if they are, whether the
new product raises different questions of public health.
Added Toxicants
Where information was provided about the levels of specific ingredients showing
they were present at higher levels than in the predicate product, there was not
adequate evidence that the changes did not result in the new product not raising
different questions of public health. Moreover, some of these ingredients have
been shown scientifically to cause both toxicological and dependence concerns.
For example, some of these ingredients are listed in the Hazardous Substances
Data Bank and have known toxicities.
Harmful and Potentially Harmful Constituents
Inadequate information regarding Harmful and Potentially Harmful Constituents
(HPHCs) in new and/or predicate tobacco products and tobacco smoke. Lacking
this information, FDA was not able to determine whether the new product raised
different questions of public health.
Change in Burn Properties
Inadequate information regarding changes in additives that could change the
burning properties of a cigarette. Lacking adequate evidence, FDA was not able
to determine whether the new product raised different questions of public health.
Increase in Free Nicotine
Inadequate information regarding the effect of increased free nicotine
(unprotonated nicotine) in smokeless tobacco products on initiation and
cessation. An increase in free nicotine may lead to a higher rate and amount of
nicotine absorbed in the body. An increase in free nicotine may cause the new
product to raise different questions of public health because initiation may
increase and/or cessation may decrease.
New Characterizing Flavor
Inadequate information regarding the effect of a new characterizing flavor in
smokeless tobacco products on product initiation and cessation. Addition of a
new characterizing flavor may cause the new product to raise different questions
of public health because initiation may increase and/or cessation may decrease.
Increase in Free Nicotine
Inadequate information regarding the effect of increased free nicotine
(unprotonated nicotine) in smokeless tobacco products on initiation and
cessation. An increase in free nicotine may lead to a higher rate and amount of
nicotine absorbed in the body. An increase in free nicotine may cause the new
product to raise different questions of public health because initiation may
increase and/or cessation may decrease.
New Characterizing Flavor
Inadequate information regarding the effect of a new characterizing flavor in
smokeless tobacco products on product initiation and cessation. Addition of a
new characterizing flavor may cause the new product to raise different questions
of public health because initiation may increase and/or cessation may decrease.
Differences in Tobacco Blend
There were significant differences in the tobacco blends between the predicate
and new tobacco products. Tobacco blend differences can result in different
levels of harmful and potentially harmful constituents.
Health Information Summary
Submitted health information summary does not comply with section 910(a)(4) of
the Federal Food, Drug, and Cosmetic Act (FD&C Act). Therefore, a marketing
order cannot be issued for the new tobacco product.
http://www.fda.gov/downloads/TobaccoProducts/Labeling/MarketingandAdvertising/UCM366584.pdf
that delineates why NO e-cigarette product currently on the market could be approved as Substantially Equivalent to a product that was on the market prior to Februay 15, 2007 (unless FDA exempts e-cigs from the 2007 grandfather date in Section 910).
The FDA also announced today that it had rejected two more SE applications for tobacco products (for a total of 10 NSE decisions by FDA). Meanwhile, the FDA has only approved 9 SE applications so far (2 for cigarettes, and 7 for RYO papers and tobacco)..
Tobacco Product Marketing Orders
Yesterday, the US GAO issued a scathing report saying the FDA needs to set time frames for its review process of Substantial Equivalence (SE) applications for tobacco products since agency has made final decisions on just 17 of 3,788 SE applications filed since 2010, Senator Burr comments
http://www.gao.gov/assets/660/657451.pdf
Richard Burr, United States Senator of North Carolina: Press Releases
New Report Highlights Shortcomings in FDA Review Process - Legislative & Regulatory News - Convenience Store News
Since it's not that long, I posted the full text of the FDA's Brief Summary of "Not Substantially Equivalent" Determinations below.
Do any vapers or vendors believe that FDA would approve an SE application for any of their e-cig products? Didn't think so.
10/25/2013
Brief Summary of Not Substantially Equivalent Determinations
FDA may find a new tobacco product to be NSE either because there is inadequate
information submitted, or because FDA finds that the new product has different
characteristics and information demonstrates that it raises different questions of public
health.
Tobacco products have been found to be not substantially equivalent to specific
predicate products due to factors such as inadequate evidence that the proposed
predicate products were valid predicates and lack of complete information on the
characteristics of the new products and the predicate products. After considering all the
evidence, the agency determined that there were differences in characteristics between
the new products and the predicate products, and there was not an adequate showing
that the new products do not raise different questions of public health requiring a
premarket tobacco product application.
The types of deficiencies FDA found in one or more of these are summarized below.
Predicate
Insufficient information for FDA to determine whether or not the tobacco product
that was referenced as a predicate was predicate-eligible. Specifically, adequate
evidence was not provided to demonstrate that the predicate product was
commercially marketed in the United States as of February 15, 2007.
Design Features
Inadequate information on design features such as ventilation and filter
efficiency. This information is needed to understand if any changes in these
characteristics are present and, if they are, whether the new product raises
different questions of public health.
Tobacco Type
Inadequate information on the type of tobacco used in the cigarette. This is a
significant deficiency because the type of tobacco can alter the levels of harmful
and potentially harmful constituents. This information is needed to understand if
any changes in these characteristics are present and, if they are, whether the
new product raises different questions of public health.
Added Toxicants
Where information was provided about the levels of specific ingredients showing
they were present at higher levels than in the predicate product, there was not
adequate evidence that the changes did not result in the new product not raising
different questions of public health. Moreover, some of these ingredients have
been shown scientifically to cause both toxicological and dependence concerns.
For example, some of these ingredients are listed in the Hazardous Substances
Data Bank and have known toxicities.
Harmful and Potentially Harmful Constituents
Inadequate information regarding Harmful and Potentially Harmful Constituents
(HPHCs) in new and/or predicate tobacco products and tobacco smoke. Lacking
this information, FDA was not able to determine whether the new product raised
different questions of public health.
Change in Burn Properties
Inadequate information regarding changes in additives that could change the
burning properties of a cigarette. Lacking adequate evidence, FDA was not able
to determine whether the new product raised different questions of public health.
Increase in Free Nicotine
Inadequate information regarding the effect of increased free nicotine
(unprotonated nicotine) in smokeless tobacco products on initiation and
cessation. An increase in free nicotine may lead to a higher rate and amount of
nicotine absorbed in the body. An increase in free nicotine may cause the new
product to raise different questions of public health because initiation may
increase and/or cessation may decrease.
New Characterizing Flavor
Inadequate information regarding the effect of a new characterizing flavor in
smokeless tobacco products on product initiation and cessation. Addition of a
new characterizing flavor may cause the new product to raise different questions
of public health because initiation may increase and/or cessation may decrease.
Increase in Free Nicotine
Inadequate information regarding the effect of increased free nicotine
(unprotonated nicotine) in smokeless tobacco products on initiation and
cessation. An increase in free nicotine may lead to a higher rate and amount of
nicotine absorbed in the body. An increase in free nicotine may cause the new
product to raise different questions of public health because initiation may
increase and/or cessation may decrease.
New Characterizing Flavor
Inadequate information regarding the effect of a new characterizing flavor in
smokeless tobacco products on product initiation and cessation. Addition of a
new characterizing flavor may cause the new product to raise different questions
of public health because initiation may increase and/or cessation may decrease.
Differences in Tobacco Blend
There were significant differences in the tobacco blends between the predicate
and new tobacco products. Tobacco blend differences can result in different
levels of harmful and potentially harmful constituents.
Health Information Summary
Submitted health information summary does not comply with section 910(a)(4) of
the Federal Food, Drug, and Cosmetic Act (FD&C Act). Therefore, a marketing
order cannot be issued for the new tobacco product.
Last edited: